Explore

TrendlineTrendline
Medical Device and Equipment Certification Market Driven by Regulatory Frameworks and Patient Safety

Medical Device and Equipment Certification Market Driven by Regulatory Frameworks and Patient Safety

Medical Device and Equipment Certification Market Driven by Regulatory Frameworks and Patient Safety
Rapid ReadRapid Read
AI Integration in Clinical Research Faces 'Last-Mile Hurdles' in Real-World Application

AI Integration in Clinical Research Faces 'Last-Mile Hurdles' in Real-World Application

Implementing Artificial Intelligence (AI) in real-world clinical research faces significant challenges, particularly concerning Good Clinical Practice (GCP) compliance and data integrity, according to Marc Wartenberger, vice president of compliance and security at CRIO. Speaking at the SCOPE Europe event, Wartenberger highlighted that while personal productivity AI tools are less concerning, those impacting adverse events or drug treatment decisions require rigorous scrutiny. The updated ICH E6(R3) guideline emphasizes risk-based workflows, but integrating AI necessitates additional checks for bias and drift. Accountability for AI-supported decisions cannot be delegated to technology, requiring human oversight and understanding. Data privacy and protection are major concerns, with warnings against plugging sensitive data into public AI tools without adequate safeguards. The validation of AI tools is also more complex than traditional software due to their continuous evolution, posing a challenge for regula...
Rapid ReadRapid Read
Florida Legislature Regulates Podiatric Use of Cellular and Tissue-Based Products, Prohibiting Fetal-Derived Materials

Florida Legislature Regulates Podiatric Use of Cellular and Tissue-Based Products, Prohibiting Fetal-Derived Materials

The Florida Legislature has enacted regulations concerning the use of cellular and tissue-based products by podiatric physicians, aiming to advance medical treatments while upholding ethical standards. The new law permits podiatric physicians to use cellular or tissue-based products not yet approved by the United States Food and Drug Administration (FDA) for treatments within their scope of practice, specifically for connective tissue, ligament, and tendon repair; wound care; or pain management. However, these products must meet stringent conditions: they must be retrieved, manufactured, and stored in FDA-registered and regulated facilities, and certified or accredited by recognized entities such as the National Marrow Donor Program or the American Association of Tissue Banks. Crucially, the legislation explicitly prohibits the use of human cells or tissues derived from a fetus or an embryo after an abortion, making such actions a third-degree felony. Podiatric physicians must also obtain informed consent ...
Rapid ReadRapid Read
Congress Considers Legislation to Regulate AI in Healthcare, Addressing Oversight and Reimbursement

Congress Considers Legislation to Regulate AI in Healthcare, Addressing Oversight and Reimbursement

Congress is actively considering new legislation to shape the regulation and use of Artificial Intelligence (AI) in healthcare. On October 29, Senate HELP Committee Chairman Bill Cassidy released a discussion draft of the Protecting Americans Through Intelligent, Ethical, and Transparent Artificial Intelligence in Health Care Act, or PATIENT AI Act. This proposed legislation aims to address critical issues within the industry, including oversight of AI-based health technologies by the U.S. Food and Drug Administration (FDA) and the Office of the National Coordinator for Health Information Technology (ONC). It also covers FDA review processes for software changes, guidance from the Department of Health and Human Services (HHS) on AI privacy and security, and the establishment of a payment pathway for qualifying AI technologies. Additionally, a separate bipartisan House proposal, the Doctors Not AI Act of 2026, focuses on AI use in health plan coverage decisions, seeking to prohibit AI systems from making ad...
Rapid ReadRapid Read
FDA Authorizes Theraclion's Sonovein Device for Noninvasive Varicose Vein Treatment

FDA Authorizes Theraclion's Sonovein Device for Noninvasive Varicose Vein Treatment

The U.S. Food and Drug Administration (FDA) has granted De Novo authorization to Theraclion for its Sonovein device. This device is designed to treat superficial venous reflux in great saphenous veins (GSV), which is the primary cause of varicose veins. This marks the first time a noninvasive focused ultrasound platform has been authorized for this condition. The FDA's decision was based on the results of the pivotal VEINRESET clinical trial, which enrolled 70 participants across four sites in the U.S. and Europe. The trial successfully met its primary endpoint, demonstrating a 96.8% GSV occlusion rate after one year. Importantly, the study reported no serious or unanticipated adverse events, with only one mild adverse event observed. Theraclion is now preparing to launch a U.S. subsidiary, Sonovein, Inc., and has already established a dedicated Category III CPT code, a crucial step towards securing insurance coverage for the treatment.
Rapid ReadRapid Read
American Medical Association Clarifies AI's Role in Healthcare, Prohibits Licensure for Nonhuman Entities

American Medical Association Clarifies AI's Role in Healthcare, Prohibits Licensure for Nonhuman Entities

The American Medical Association (AMA) has adopted a new policy clarifying that while artificial intelligence (AI) can assist physicians in healthcare, it cannot be granted physician licensure, professional titles, or certification to practice medicine. This policy, adopted at the 2026 AMA Interim Meeting, emphasizes that AI-enabled technologies should be integrated into physician-led teams and used under the direction of the treating physician. AMA President Willie Underwood III, MD, MSc, MPH, stated that patients deserve to know who is responsible for their care and that physicians require authority, oversight, and liability protections when AI is part of the care team. The policy also calls for model legislation to differentiate between the authorization of medical technology and professional licensure, and to prohibit misrepresenting nonhuman entities with titles reserved for physicians. Furthermore, the AMA will advocate for safeguards to prevent AI developers from using patients' clinical data for pr...
Rapid ReadRapid Read
Family Farmstead Dairy Recalls Cheddar Cheese in 12 States Over Listeria Contamination Concerns

Family Farmstead Dairy Recalls Cheddar Cheese in 12 States Over Listeria Contamination Concerns

Family Farmstead Dairy has issued a recall for its 8-ounce Raw Mild Cheddar and Raw Sharp Cheddar products due to potential Listeria contamination. The recall affects all lot codes with dates of October 16, 2027, or earlier. These products were distributed to retail stores across 12 states: New York, New Jersey, Vermont, New Hampshire, Massachusetts, Pennsylvania, Rhode Island, Connecticut, Delaware, Virginia, West Virginia, and Tennessee. This announcement follows a previous recall in October by the same company for certain raw cheddar products due to possible E. coli contamination. Customers who have purchased the affected cheese are advised to return it to the place of purchase or contact Family Farmstead Dairy for assistance.
Rapid ReadRapid Read
Cleveland Clinic Trial Shows CRISPR Gene Editing Significantly Reduces Triglycerides in Patients

Cleveland Clinic Trial Shows CRISPR Gene Editing Significantly Reduces Triglycerides in Patients

A Phase 1b clinical trial conducted by Cleveland Clinic has demonstrated that a single infusion of the experimental CRISPR-Cas9 gene-editing therapy, CTX310, led to a substantial reduction in triglyceride levels in adults with severe hypertriglyceridemia. The trial involved 10 participants, all of whom had diabetes and fasting triglycerides exceeding 500 mg/dL, with some having a history of pancreatitis. At 30 days post-treatment, patients experienced an average 63% decrease in triglycerides and a 65% mean reduction in ANGPTL3, the target protein. The therapy works by disabling the ANGPTL3 gene in liver cells, mimicking a natural genetic variation associated with lower lipid levels. The study reported no serious treatment-related side effects, though one participant experienced a moderate infusion reaction that resolved. These preliminary findings were presented at the American Heart Association's Scientific Sessions in Chicago and represent the first look at CTX310 in this high-risk patient population.
Rapid ReadRapid Read
FDA, CDC, and USDA Study Reveals Minimal Progress in Reducing Foodborne Illnesses

FDA, CDC, and USDA Study Reveals Minimal Progress in Reducing Foodborne Illnesses

A joint study by researchers from the FDA, CDC, and USDA has found that the United States has made 'none to very slight' progress toward national foodborne illness reduction targets. The study, published in the Journal of Food Protection, examined nearly four decades of data related to the Healthy People initiative, which sets national health objectives with 10-year targets. Specifically, none of the Healthy People 2020 targets for reducing foodborne illnesses were met. The most recent data for Healthy People 2030 indicates an increasing incidence of infections from Campylobacter, Listeria monocytogenes, and Shiga toxin-producing E. Coli (STEC), while Salmonella infections have remained level. Between 2011 and 2022, over 9,000 foodborne illness outbreaks were reported across all 50 states, costing Americans an estimated $75 billion annually in medical care, lost productivity, and premature deaths.
Rapid ReadRapid Read
US FDA Mandates Unique Device Identifiers (UDI) on Medical Device Labels and Packages

US FDA Mandates Unique Device Identifiers (UDI) on Medical Device Labels and Packages

Under U.S. FDA regulations, every medical device label and each device package must carry a Unique Device Identifier (UDI). This requirement ensures traceability and identification throughout the device's lifecycle. For reusable devices that undergo reprocessing between uses, a permanent UDI mark must also be directly on the device itself. A UDI consists of two parts: a device identifier, which identifies the labeler and the specific version or model, and a production identifier, which can include the lot or batch number, serial number, manufacturing date, and expiration date. The UDI must be presented in two forms: easily readable plain text and automatic identification and data capture (AIDC) technology, typically a linear barcode or Data Matrix. Device identifier data is submitted to the FDA’s Global Unique Device Identification Database (GUDID).
Rapid ReadRapid Read
AI Integration in Clinical Trials Raises Significant Data Security Concerns for Healthcare and Biotech Sectors

AI Integration in Clinical Trials Raises Significant Data Security Concerns for Healthcare and Biotech Sectors

The increasing integration of Artificial Intelligence (AI) in healthcare and biotech research, particularly within clinical trials, is introducing new and complex data security challenges. While AI is becoming an expected part of daily operations, with 75% of U.S. health systems using at least one AI application, it also creates additional vulnerabilities for sensitive patient records and proprietary research data. Healthcare remains a prime target for cybercriminals, with the average data breach costing $7.42 million and taking 279 days to identify and contain. The 2024 Change Healthcare ransomware attack, which affected 192.7 million individuals due to a single missing control, highlights the severe consequences of security lapses. AI models and their training datasets are now valuable targets for attackers, necessitating robust data protection strategies that extend to every model, dataset, and environment involved in clinical trial information. The FDA and EMA have jointly released ten guiding principl...
Rapid ReadRapid Read
FDA Issues Warning Letter Against Unapproved Wharton's Jelly and Exosome Injections for Orthopedic Conditions

FDA Issues Warning Letter Against Unapproved Wharton's Jelly and Exosome Injections for Orthopedic Conditions

The U.S. Food and Drug Administration (FDA) has issued a warning letter to an IV hydration clinic for selling unapproved umbilical cord products, including Wharton's jelly, and exosome products as IV treatments. The FDA stated that these products are unapproved drugs and unlicensed biologics. The clinic's website advertised these products for conditions such as joint pain, arthritis pain, inflammation, damaged tissue, and hip pain. The FDA clarified that umbilical cord products, including Wharton's jelly, are not approved for any orthopedic condition like arthritis or joint pain, and there are currently no FDA-approved exosome products. The only legal use for these products in the U.S. for such conditions is within an FDA-cleared research study.